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Both Prediabetes and Type 2
Diabetes Are Associated With
Lower Heart Rate Variability:
The Maastricht Study
Diabetes Care 2020;43:1126–1133 | https://doi.org/10.2337/dc19-2367
OBJECTIVE
Low heart rate variability (HRV), a marker for cardiac autonomic dysfunction, is a
known feature of type 2 diabetes, but it remains incompletely understoodwhether
this also applies to prediabetes or across the whole glycemic spectrum. Therefore,
we investigated the association among prediabetes, type 2 diabetes, andmeasures
of glycemia and HRV.
RESEARCH DESIGN AND METHODS
In the population-basedMaastricht Study (n5 2,107; mean6 SD age 596 8 years;
52%men;normal glucosemetabolism[n51,226], prediabetes [n5331], and type2
diabetes [n5 550, oversampled]), we determined 24-h electrocardiogram-derived
HRV in time and frequency domains (individual z-scores, based upon seven and six
variables, respectively).We used linear regressionwith adjustments for age, sex, and
major cardiovascular risk factors.
RESULTS
After adjustments, both time and frequency domain HRV were lower in pre-
diabetes and type 2 diabetes as compared with normal glucose metabolism
(standardized b [95% CI] for time domain: 20.15 [20.27; 20.03] and 20.34
[20.46; 20.22], respectively, P for trend <0.001; for frequency domain: 20.14
[20.26; 20.02] and 20.31 [20.43; 20.19], respectively, P for trend <0.001). In
addition, 1-SD higher glycated hemoglobin, fasting plasma glucose, and 2-h postload
glucose were associated with lower HRV in both domains (time domain: 20.16
[20.21; 20.12], 20.16 [20.21; 20.12], and 20.15 [20.20; 20.10], respectively;
frequency domain: 20.14 [20.19; 20.10], 20.14 [20.18; 20.09], and 20.13
[20.18; 20.08], respectively).
CONCLUSIONS
Both prediabetes and type 2 diabetes were independently associated with lower
HRV. This is further substantiatedby independent continuousassociations between
measuresof hyperglycemia and lowerHRV. Thesedata strongly suggest that cardiac
autonomic dysfunction is already present in prediabetes.
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Cardiovascular disease in type 2 diabetes
is clinically diverse, ranging from myo-
cardial infarction, stroke, and intermit-
tent claudication (1) to sudden death,
arrhythmia, silent ischemia, and heart
failure (2–4). Diabetes is associated with
atherothrombosis (5), arterial stiffening
(6), and microvascular dysfunction (7),
and these aremajor pathways explaining
this clinical diversity. Another mecha-
nism that is thought to contribute is
diabetes-associated cardiac autonomic
dysfunction (8).
Cardiac autonomic function can be non-
invasively assessed by calculation of heart
rate variability (HRV), which reflects the
interaction of the sympathetic and para-
sympathetic parts of the autonomic ner-
vous system on the sinus node (9). Low
HRV is a validated measure of cardiac
autonomic dysfunction and is associated
with an increased risk of ventricular ar-
rhythmias and sudden cardiac arrest (10).
Interestingly, evidence is accumulat-
ing that many abnormalities observed in
type 2 diabetes are already present, al-
though less severe, in prediabetes (7).
Indeed, prediabetes is also associated
with greater risk of cardiovascular dis-
ease (11). In addition, next to theglucose
metabolism status classification, contin-
uous measures of hyperglycemia have
also been shown to be associated with
cardiovascular disease (12,13). This rai-
ses the possibility that prediabetes, as
compared with normal glucose metab-
olism, is also associated with cardiac
autonomic dysfunction.
Some population-based studies on the
associations of prediabetes and type 2
diabetes with HRV have suggested that
this is the case (14–19). However, these
studies have found inconsistent results
using various individual HRV measures
(14–19) or did not adjust for important
potential confounders, such as physical
activity (14,15,17,18). Importantly, all
previous studies have only used short-
term electrocardiogram (ECG) record-
ings (;5 min) (14–19), whereas HRV
derived from 24-h ECG is a more accurate
reflection of cardiac autonomic function
(9,20).
In view of these considerations, we
tested, inapopulation-basedcohort study,
the hypothesis that prediabetes and di-
abetes, as well as continuous measures
of hyperglycemia (i.e., glycated hemo-
globin [HbA1c] and fasting and2-hplasma
glucose from an oral glucose tolerance
test [OGTT]) are associated with cardiac
autonomic dysfunction, as measured by
time and frequency domain HRV derived
from 24-h ECGs.
RESEARCH DESIGN AND METHODS
Study Population and Design
Weused data from theMaastricht Study,
an observational, prospective, population-
based cohort study. The rationale and
methods have been described previously
(21). In brief, the study focuses on the
etiology, pathophysiology, complications,
and comorbidities of type 2 diabetes and
is characterized by an extensive pheno-
typingapproach. Eligibleparticipantswere
individuals between 40 and 75 years of
age and living in the southern part of the
Netherlands. Participants were recruited
through mass media campaigns and from
the municipal registries and the regional
Diabetes Patient Registry via mailings.
Recruitment was stratified according to
known type 2 diabetes status, with an
oversampling of individuals with type 2
diabetes, for reasons of efficiency. The
present report includes cross-sectional
data from the first 3,541 participants,
who completed the baseline survey be-
tween November 2010 and September
2013. The examinations of each partici-
pant were performed within a time win-
dowof3months. The studywasapproved
by the institutional medical ethics com-
mittee(NL31329.068.10)andtheMinister
of Health, Welfare and Sport of the Neth-
erlands (permit 131088–105234-PG) and
was conducted in accordance with the
Declarations of Helsinki. All participants
gave written informed consent.
Assessment of Glucose Metabolism
Status
In order to determine glucose metabo-
lism status, all participants (except those
who used insulin) underwent a standard-
ized 2-h 75-g OGTT after an overnight
fast. For safety reasons, participants with
a fasting glucose level .11.0 mmol/L, as
determined by finger prick, did not un-
dergo the OGTT. For these individuals,
fasting glucose level and information
about diabetes medication were used
to determine glucose metabolism status.
Glucose metabolism status was defined
according to the World Health Organi-
zation 2006 criteria as normal glucose
metabolism, prediabetes (impaired fasting
glucose and/or impaired glucose toler-
ance), and type 2 diabetes (22).
Assessment of HRV
All ECGswere recordedbyuseofa12-lead
Holter system (Fysiologic ECG Services,
Amsterdam, the Netherlands) over a 24-h
period. During recording time, partici-
pants were asked to follow their normal
daily activities, except that they were
asked not to take a shower or a bath.
Recordings were analyzed with propri-
etary Holter Analysis Software at Fysio-
logic ECGServiceswith analgorithmthat
excluded nonsinus cardiac cycles (e.g.,
artifacts and premature/ectopic beats),
validated by manual inspection after-
ward. The software from Fysiologic pro-
vided the intervals between the individual
R waves of sinus beats (i.e., interbeat
intervals [IBIs], in milliseconds). From
the obtained IBIs, HRVwas calculated by
use of the publicly available free GNU
Octave software (23), according to the
standard time and frequency domain
measures defined by the 1996 Task Force
document on HRV (9) and recently up-
dated recommendations (24). The mini-
mum duration of the recording for HRV
analysis was 18 h after exclusion of non-
sinus cardiac cycles. As time domain
measures, we calculated the SD of all
normal-to-normal (NN) intervals (SDNN,
in milliseconds); the SD of the averages of
NN intervals in all 5-min segments of the
entire recording (SDANN, inmilliseconds);
the square root of themean of the sumof
squares of differences between adjacent
NN intervals (RMSSD, in ms); the mean of
the SDs of all NN intervals for all 5-min
segments of the entire recording (SDNN
index, in milliseconds); the SDs of differ-
ences between adjacent NN intervals
(SDSD, in milliseconds); the number of
pairs of adjacent NN intervals differing
by.50ms in the entire recording (NN50
count); and the NN50 count divided by
the total number of all NN intervals
(pNN50, a percentage). As frequency
domainmeasures, we used the Fast Four-
ier Transform to calculate the variance of
all NN intervals#0.4 Hz (total power [TP],
in milliseconds squared); power in the
ultralow-frequency range (ULF, in milli-
seconds squared) (#0.003 Hz); power in
the very-low-frequency range (VLF, in
milliseconds squared) (0.003–0.04 Hz);
power in the low-frequency range (LF, in
milliseconds squared) (0.04–0.15 Hz);
power in the high-frequency range (HF,
in milliseconds squared) (0.15–0.4 Hz);
and the LF/HF ratio. Individual z-scores
were calculated for the time and frequency
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domain measures and combined in an
overall time domain variable ([SDNN 1
RMSSD 1 SDANN 1 SDNN index 1
pNN50]/5) and an overall frequency
domain variable ([TP 1 ULF 1 VLF 1
LF1HF]/5). SDSD,NN50, andLF/HFwere
excluded from the z-score calculation
due to the fact that these variables
were derived from variables already in-
cluded in the overall score (i.e., SDNN,
SDANN, LF, and HF).
Measurement of Covariates
We assessed history of cardiovascular
disease, duration of diabetes, education
level (low, intermediate, and high), smok-
ing status (never, former, and current),
alcohol use (none, low, and high) by
questionnaire, and physical activity by
questionnaire (total activity hours per
week) and accelerometer (mean step-
ping time per hour; activPAL3). We
assessed use of medication during an
interview in which we registered ge-
neric name, dose, and frequency. We
measured body weight, height, BMI,
waist circumference, ambulatory 24-h
blood pressure, plasma glucose levels,
HbA1c, plasma insulin, HOMA of insulin
resistance (HOMA2-IR; based on fast-
ing plasma glucose and insulin), the
Matsuda index of insulin sensitivity
(based on plasma glucose and insulin
levels during an OGTT), and plasma
lipid profile as described elsewhere
(21). Estimated glomerular filtration
rate (in mL/min/1.73 m2) was calcu-
lated with the Chronic Kidney Disease
Epidemiology Collaboration equation
based on both serum creatinine and
serum cystatin C (25).
Analytical Sample
From the initial 3,451 participants in-
cluded,we excluded individualswith other
types of diabetes than type 2 diabetes
(n 5 41). Of the remaining sample, we
excluded those in whom HRV could not
be adequately assessed (no 24-h ECG
available due to logistics [n 5 856],
ECG registration ,18 h [n 5 16], or
arrhythmia [n 5 22]). Of the remain-
ing 2,506 participants, 2,107 had com-
plete data on potential confounders
and were included in the final study
population (Supplementary Fig. 1). The
characteristics of individuals excluded
from the analysis compared with those
included were largely similar, but indi-
viduals excluded from the analysis had a
somewhat more adverse cardiovascular
risk profile (Supplementary Table 1).
Statistical Analyses
We used multivariable linear regression
analysis to determine the associations of
glucosemetabolism (normal glucoseme-
tabolism, prediabetes, and type 2 diabe-
tes), fasting plasma glucose, 2-h postload
plasmaglucose levels fromtheOGTT, and
HbA1c with time and frequency domain
HRVs. For linear trend analyses, the cat-
egorical variable glucose metabolism sta-
tus (normal glucose metabolism 5 0,
prediabetes5 1, and type 2 diabetes5 2)
was used in the regression models. To
assess regression coefficients per glu-
cose metabolism group, we used pair-
wise analyses with dummy variables for
prediabetes and type 2 diabetes. To test
for a linear relationship of lower HRV
across deteriorating glucose metabolism
status, we compared the aforementioned
models with a likelihood ratio test (in
which the null hypothesis states that
there is a linear response).
We adjusted for the following cova-
riates: model 1 adjusted for age, sex, and
education level; model 2 additionally ad-
justed for cardiovascular risk factors that
have previously been associated with
lower HRV (26) (i.e., BMI, alcohol con-
sumption, smoking behavior, self-reported
physical activity, systolic blood pressure,
total-to-HDL cholesterol levels, and use
of antihypertensive and lipid-modifying
drugs); and model 3 additionally adjusted
for history of cardiovascular disease and
estimated glomerular filtration rate.
To test whether associations differed by
sex, interaction terms (prediabetes * sex,
type 2 diabetes * sex, and measures of
hyperglycemia * sex) were added to the
regression models.
Weperformed several additional anal-
yses to test the robustness of our find-
ings: 1) we repeated the analyses with
individual measures of HRV as the out-
come; 2) we additionally adjusted for
heart period (i.e., mean IBI) and markers
of insulin resistance (i.e., fasting plasma
insulin, HOMA-IR, and theMatsuda index
of insulin sensitivity), although this may
cause overadjustment: heart period may
be intrinsically linked to HRV, but is also a
reflection of autonomic function (27),
and insulin resistance has been suggested
to be associated with lower HRV (17), but
may lie on the causal pathway of deteri-
orating glucose metabolism to autonomic
dysfunction; 3) we excluded individuals
who used antihypertensive medication,
as it has been suggested that the use of
b-blockers, nondihydropiridine calcium
channel blockers, diuretics, and renin-
angiotensin system blockers may influ-
ence HRV (28); and 4) we adjusted for
objectively measured physical activity by
an accelerometer instead of physical
activity based on questionnaires, for
waist circumference instead of BMI, and
for 24-h systolic blood pressure instead of
office systolic blood pressure. We did this
inadditional rather thanthemainanalyses
because participants more often had miss-
ing dataon these variables (analyses done
in n 5 1,610 for objectively measured
physical activity, n 5 2,105 for waist
circumference, and n 5 1,944 for 24-h
blood pressure).
All statistical analyseswere performed
with IBM SPSS version 25.0 for Windows
(IBM Corp., Somers, NY). A two-sided P
value of ,0.05 was considered statisti-
cally significant, except for interaction
analyses, in which Pinteraction ,0.10 was
considered statistically significant.
RESULTS
Characteristics of Study Population
The study population consisted of 2,107
individuals with amean6 SD age of 59.7
6 8.2 years, of whom 51.3% were men
(Table1). Individualswith type2diabetes
were, by design, oversampled (26.1%).
Fromnormal glucosemetabolismto type2
diabetes, age, BMI, blood pressure, and use
of antihypertensive and lipid-modifying
medication were higher. In addition, in-
dividuals with prediabetes or type 2 di-
abetes were, as compared with normal
glucose metabolism, more often men and
current smokers, more often had a history
of cardiovascular disease, and had lower
amounts of physical activity, lower esti-
matedglomerularfiltration rate, and lower
estimates of HRV (Table 1).
Glucose Metabolism Status and HRV
The composite scores for time and fre-
quency domain HRV were lower in in-
dividuals with prediabetes and type 2
diabetes as compared with normal glu-
cosemetabolism (Table2 [crudemodel]).
Adjustment for age, sex, and education
level attenuated the differences between
individuals with type 2 diabetes or pre-
diabetes and normal glucosemetabolism,
but the associations remained statisti-
cally significant (P for trend ,0.001).
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Table 1—General characteristics and HRV measures of the study population according to glucose metabolism status
Characteristic
Normal glucose
metabolism (n 5 1,226)
Prediabetes
(n 5 331)
Type 2 diabetes
(n 5 550)
Demographics
Age, years 57.9 6 8.1 61.4 6 7.7 62.5 6 7.6
Men 534 (43.6) 180 (54.4) 367 (66.7)
Education level
Low 297 (24.2) 118 (35.6) 250 (45.5)
Intermediate 351 (28.6) 93 (28.1) 159 (28.9)
High 578 (47.1) 120 (36.3) 141 (25.6)
Lifestyle variables
Smoking behavior
Never 483 (39.4) 98 (29.6) 152 (27.6)
Former 595 (48.5) 194 (58.6) 323 (58.7)
Current 148 (12.1) 39 (11.8) 75 (13.6)
Alcohol consumption
None 171 (13.9) 51 (15.4) 162 (29.5)
Low 703 (57.3) 178 (53.8) 281 (51.5)
High 352 (28.7) 102 (30.8) 107 (19.5)
Physical activity, h/week 15.2 6 8.2 14.3 6 7.7 12.7 6 8.2
Clinical characteristics
BMI, kg/m2 25.5 6 3.6 27.8 6 4.1 29.7 6 5.1
History of cardiovascular disease 141 (11.7) 43 (13.0) 154 (28.0)
eGFR, mL/min/1.73 m2 90.2 6 13.2 86.9 6 13.9 84.8 6 17.3
Fasting plasma glucose, mmol/L* 5.2 6 0.4 5.9 6 0.6 7.9 6 2.1
2-h postload glucose, mmol/L* 5.4 6 1.1 8.2 6 1.8 14.5 6 3.8
HbA1c, %* 5.5 6 0.3 5.7 6 0.4 6.9 6 1.1
HbA1c, mmol/mol* 36.1 6 3.7 38.8 6 4.4 51.8 6 11.5
Diabetes duration, years d d 5.0 (3.0–11.0)
Office systolic blood pressure, mmHg 130.9 6 17.2 138.1 6 17.7 142.3 6 17.5
Office diastolic blood pressure, mmHg 75.5 6 9.8 78.2 6 9.5 77.5 6 9.6
Office heart rate, bpm 65.9 6 9.6 68.3 6 11.1 71.4 6 12.5
Total-to-HDL cholesterol ratio 3.6 6 1.2 3.9 6 1.3 3.8 6 1.2
Total cholesterol, mmol/L 5.5 6 1.0 5.5 6 1.2 4.5 6 1.0
HDL cholesterol, mmol/L 1.7 6 0.5 1.5 6 0.4 1.3 6 0.4
LDL cholesterol, mmol/L 3.4 6 0.9 3.3 6 1.1 2.5 6 0.9
Triglycerides, mmol/L 1.1 (0.8–1.4) 1.3 (1.0–1.8) 1.5 (1.1–2.2)
Use of lipid-modifying medication 209 (17.0) 113 (34.1) 400 (72.7)
Use of antihypertensive medication 261 (21.3) 145 (43.8) 404 (73.5)
b-Blockers 104 (8.5) 74 (22.4) 193 (35.1)
Diuretics 83 (6.8) 62 (18.7) 188 (34.2)
Calcium antagonists 46 (3.8) 22 (6.6) 118 (21.5)
ACE inhibitors 73 (6.0) 28 (8.5) 142 (25.8)
Angiotensin II inhibitors 98 (8.0) 75 (22.7) 180 (32.7)
Use of glucose-lowering medication d d 418 (76.0)
Insulin d d 101 (18.4)
Metformin d d 372 (67.6)
Sulfonylureas d d 114 (20.7)
Thiazolidinediones d d 5 (0.9)
GLP-1 analogs d d 4 (0.7)
DPP-4 inhibitors d d 33 (6.0)
HRV
Time domain
Composite score, SD 0.15 6 0.93 20.10 6 0.84 20.33 6 0.95
SDNN, ms 141.6 6 37.3 131.3 6 37.5 118.6 6 35.0
SDANN, ms 127.8 6 35.8 118.7 6 36.8 107.0 6 32.9
RMSSD, ms 29.9 6 13.9 27.8 6 13.1 27.4 6 16.9
SDNN index, ms 56.4 6 16.8 51.9 6 14.6 47.2 6 17.6
SDSD, ms 26.9 6 15.0 27.9 6 13.2 24.8 6 16.5
NN50, count 6,697 (3,174–12,304) 5,266 (2,546–10,283) 4,244 (1,777–8,952)
pNN50, % 7.1 (3.2–13.4) 5.5 (2.6–11.1) 4.4 (1.7–9.8)
Frequency domain
Composite score, SD 0.16 6 0.99 20.10 6 0.80 20.32 6 0.91
TP, ms2 12,579 (8,776–17,228) 10,627 (7,072–15,876) 8,678 (5,763–13,019)
ULF, ms2 10,798 (7,409–14,881) 8,961 (5,867–13,847) 7,379 (4,731–11,092)
Continued on p. 1130
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Additional adjustment for cardiovascu-
lar risk factors (model 2), history of
cardiovascular disease, and estimated glo-
merular filtration rate (model 3) further
attenuated the differences in HRV be-
tween individuals with type 2 diabetes
or prediabetes and normal glucose me-
tabolism, but the associations remained
statistically significant. Regression co-
efficients in prediabetes were consis-
tently approximately one-half of the type
2diabetescoefficients (P for trend,0.001)
(Table 2 [model 3] and Fig. 1). Possible
confounders, in the fully adjusted model,
that were associated with HRV in the time
domain were age (b 5 20.02 [95% CI
20.03; 20.02]), female sex (b 5 20.27
[20.36; 20.19]), BMI (b 5 20.014
[20.024;20.004]), total-to-HDL cho-
lesterol ratio (b520.07 [20.10;20.03]),
alcohol use (b520.28 [20.41;20.16]),
and smoking behavior (b 5 20.25
[20.38; 20.13]); b values indicate
the SD change in HRV per unit higher
age (years), BMI (kilograms per meter
squared), or total-to-HDL cholesterol ra-
tio, being female or a current (vs. never)
smoker, or beingahighalcohol consumer
(vs. none). Similar results were found for
HRV in the frequency domain (data not
shown). Continuous measures of hyper-
glycemia (i.e., HbA1c, fasting plasma glu-
cose, and 2-h postload glucose) were all
linearly inversely associated with HRV in
both time and frequency domains (P ,
0.001) (Table 2 [model 3] and Fig. 2).
Additional Analyses
Because we did not observe consistent
patterns of interaction with sex, we did
not stratify analyses by sex. When we
analyzed the individual measures of time
and frequency domain HRV as the out-
come, associations were similar to those
of the analyses based on the composite
HRV scores, except for the LF/HF ratio, in
which associations were not statistically
significant (Supplementary Table 3 and
Supplementary Fig. 2). When we addi-
tionally adjusted for heart period (i.e.,
mean IBI), associations were attenu-
ated but remained statistically significant
(Supplementary Table 4). When we ad-
ditionally adjusted for markers of insulin
resistance, results did not materially
change. Exclusion of individuals who
used antihypertensive medication also
did not materially change the results
(Supplementary Table 5). When we ad-
justed for stepping time (i.e., objectively
measured physical activity) instead of
physical activity by questionnaire, for
waist circumference instead of BMI, or
for 24-h systolic blood pressure instead
of office systolic blood pressure, results
again remained similar (Supplementary
Table 6).
CONCLUSIONS
The results of the current study demon-
strate that both prediabetes and type 2
diabetes were associated with lower
Table 1—Continued
Characteristic
Normal glucose
metabolism (n 5 1,226)
Prediabetes
(n 5 331)
Type 2 diabetes
(n 5 550)
VLF, ms2 1,164 (812–1,718) 1,015 (714–1,477) 795 (539–1,228)
LF, ms2 413 (242–657) 327 (204–515) 246 (139–413)
HF, ms2 94 (54–162) 75 (47–134) 62 (34–121)
LF/HF 4.7 6 2.5 4.7 6 2.5 4.4 6 2.6
Data are reported as mean6 SD, median (interquartile range), or number (percentage). bpm, beats per minute; DPP-4, dipeptidyl peptidase 4; eGFR,
estimated glomerular filtration rate; GLP-1, glucagon-like peptide 1. *Data available for fasting plasma glucose, n5 2,105; for 2-h postload glucose,
n 5 1,982; and for HbA1c, n 5 2,102.
Table 2—Associations among glucose metabolism status and measures of glycemia (i.e., HbA1c, fasting plasma glucose, and
2-h postload glucose) and HRV
HRV measure Prediabetes
Type 2
diabetes P for trend HbA1c* P
Fasting
plasma glucose* P
2-h
postload glucose* P
Time domain†
Crude 20.26 (20.37;20.14) 20.44 (20.53;20.34) ,0.001§ 20.22 (20.26;20.18) ,0.001 20.21 (20.25;20.17) ,0.001 20.20 (20.24;20.16) ,0.001
Model 1 20.23 (20.35;20.11) 20.42 (20.52;20.32) ,0.001§ 20.20 (20.24;20.16) ,0.001 20.20 (20.24;20.16) ,0.001 20.17 (20.21;20.13) ,0.001
Model 2 20.16 (20.28;20.04) 20.35 (20.47;20.23) ,0.001§ 20.16 (20.21;20.12) ,0.001 20.16 (20.21;20.12) ,0.001 20.15 (20.20;20.11) ,0.001
Model 3 20.15 (20.27;20.03) 20.34 (20.46;20.22) ,0.001§ 20.16 (20.21;20.12) ,0.001 20.16 (20.21;20.12) ,0.001 20.15 (20.20;20.10) ,0.001
Frequency
domain‡
Crude 20.26 (20.38;20.15) 20.44 (20.54;20.34) ,0.001§ 20.21 (20.25;20.17) ,0.001 20.20 (20.24;20.16) ,0.001 20.20 (20.24;20.15) ,0.001
Model 1 20.23 (20.34;20.11) 20.41 (20.51;20.31) ,0.001§ 20.19 (20.23;20.15) ,0.001 20.19 (20.23;20.15) ,0.001 20.16 (20.20;20.12) ,0.001
Model 2 20.15 (20.27;20.03) 20.31 (20.43;20.19) ,0.001§ 20.14 (20.19;20.10) ,0.001 20.14 (20.19;20.10) ,0.001 20.13 (20.18;20.08) ,0.001
Model 3 20.14 (20.26;20.02) 20.31 (20.43;20.19) ,0.001§ 20.14 (20.19;20.10) ,0.001 20.14 (20.18;20.09) ,0.001 20.13 (20.18;20.08) ,0.001
Data are b (95% CI) unless otherwise indicated. For glucose metabolism status, regression coefficients (b) represent mean difference in HRVmeasure
with normal glucose metabolism as reference. For measures of glycemia, regression coefficients represent SD difference in HRV measure per 1-SD
increment in glucosemeasure (1 SD is equivalent to, forHbA1c, 0.87%; for fasting plasma glucose, 1.65mmol/L; and for 2-hpostloadglucose, 4.20mmol/L).
Model 1was adjusted for age, sex, and education level;model 2was additionally adjusted for BMI, total-to-HDL cholesterol ratio, alcohol consumption,
smoking behavior, physical activity, systolic blood pressure, and use of lipid-modifying and antihypertensivemedication; andmodel 3 was additionally
adjusted for history of cardiovascular disease and estimated glomerular filtration rate. *Analyses performed in, for HbA1c, n5 2,070; for fasting plasma
glucose, n5 2,073; and for 2-h postload glucose, n5 1,955. †Time domain z-score combines SDNN, SDANN, RMSSD, SDNN index, SDSD, NN50, and
pNN50. ‡Frequency domain z-score combines TP, ULF, VLF, LF, and HF. §P value for likelihood ratio test.0.05, which indicates that there is a linear
response of lower HRV across deteriorating glucose metabolism status.
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HRV. The amount by which HRV was
lower in prediabetes (as comparedwith
normal glucose metabolism) was ap-
proximately half of that in type 2 di-
abetes in both time and frequency domains.
In addition, continuous measures of glyce-
mia (HbA1c, fasting, or 2-h postload plasma
glucose levels) were linearly associated
with HRV, which suggests a graded decline
in HRV with worsening glucose tolerance.
These associations were independent of
major cardiovascular risk factors. There-
fore, our results support the concept
that cardiac autonomic dysfunction occurs
before the diagnosis of type 2 diabetes
andmay play a role in the development of
cardiovascular diseases in prediabetes
and early in the course of type 2 diabetes.
This is thefirst population-based study
to consistently show that cardiac auto-
nomic dysfunction is a feature of pre-
diabetes and type 2 diabetes. Importantly,
and in contrast to previous population-
based studies (14–19), we found that
virtually all time and frequency domain
measures of HRV, either in a composite
score or as individual measures, were
associated with worsening glucose tol-
erance. This may be explained by the
fact that we used the more accurate
24-h ECG-derived HRV as opposed to
HRV derived from short-term ECG re-
cordings. In addition, we were able to
adjust for a large series of potential con-
founders, including (objectivelymeasured)
physical activity.
We found a graded decline in car-
diovascular autonomic function from
normal glucose metabolism to type 2 di-
abetes, as supported by linear trends
that worsening glucose tolerance was
associated with lower HRV. In addition,
individuals with prediabetes had statis-
tically significantly lower HRV compared
with individuals with normal glucose
metabolism status, which indicates that
cardiac autonomic dysfunction pre-
cedes the clinical diagnosis of type 2
diabetes. We observed such associa-
tions across the whole spectrum of
hyperglycemia (i.e., we found statisti-
cally significant associations of higher
HbA1c and fasting and 2-h postload
plasma glucose with lower HRV).
We used composite scores of time and
frequency domain HRV measures to as-
sess cardiac autonomic function. The ad-
vantage of such an approach is that, if all
measures reflect similar underlying path-
ophysiology, the influence of biological
variability of its components is reduced
(29), and the chance of a type 1 error is
lower. Nonetheless, when we investi-
gated HRV measures individually, we
found that worsening glucose tolerance
showed directionally similar associations
with lower HRV for every individual mea-
sure, except for the LF/HF ratio. However,
the use of the LF/HF ratio as a marker of
sympathetic-parasympathetic (im)balance
has been criticized due to its over-
simplified reflection of a nonlinear phe-
nomenon (30).
Hyperglycemia may cause cardiac au-
tonomic dysfunction via increased oxi-
dative stress, endothelial dysfunction,
and the formationof advanced glycation
end products, all of which may lead to
neuronal damage and subsequent au-
tonomic dysfunction (31). In addition,
the association between hyperglycemia
and autonomic dysfunction may be bi-
directional. It has been suggested that
autonomicdysfunction causes hypergly-
cemia via impaired insulin release by the
pancreas, increased glucose production
by the liver, and impaired glucose up-
take and insulin resistance in skeletal
muscles (32). Indeed, several studies have
shown that cardiac autonomic dysfunc-
tion measured by high heart rate or low
HRV is associated with incident type 2
diabetes (33,34). Hence, it is possible
that a vicious cycle of hyperglycemiaand
cardiac autonomic dysfunction exists.
Note, however, that results remained
similar after adjustment for markers of
insulin resistance (i.e., plasma insulin,
HOMA2-IR, and the Matsuda index).
After adjustment for heart period, the
associations remained statistically sig-
nificant but were attenuated. This may
be partially due to overadjustment, be-
cause mean heart period is also a re-
flection of cardiac autonomic function
(27).
Strengths of this study include the
population-based approach with an over-
sampling of type 2 diabetes, which
enabled a more accurate comparison of
individuals with and without type 2 di-
abetes, and the use of themore accurate
24-h ECGs to calculate HRV. In addition,
we assessed a large series of potential
Figure 1—Multivariable adjusted differences in time domain (A) and frequency domain HRV (B) between individuals with prediabetes and type 2
diabetes (T2D) comparedwith individualswithnormal glucosemetabolism(NGM).Point estimates representSDdifferencewith95%CIs in timedomain
and frequency domain HRV for prediabetes and type 2 diabetes compared with NGM. Model 1 was adjusted for age, sex, and education level. Model 3
was additionally adjusted for BMI, total-to-HDL cholesterol ratio, alcohol consumption, smoking behavior, physical activity, systolic blood pressure, use
of lipid-modifying and antihypertensive medication, history of cardiovascular disease, and estimated glomerular filtration rate. *P for trend ,0.001.
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confounders, including objectively mea-
sured physical activity (next to question-
naires) and 24-h blood pressures (next to
office blood pressures).
Our study had some limitations. First,
due to the cross-sectional design of our
study,anycausal inferenceshouldbemade
with caution. As mentioned previously, it is
possible that a bidirectional association
exists. Second, the use of antihyperten-
sive and glucose-lowering medication
may have influenced the results.
However, when we excluded individuals
who used antihypertensive medication,
results remained similar. Removal of the
influence of glucose-lowering medication
was not feasible due to the observa-
tional nature of this study, and this may
have caused an underestimation of our
results. Of note, despite relatively well-
controlled glycemic levels, we still ob-
served significant differences in HRV in
type 2 diabetes compared with normal
glucose metabolism. Third, results from
the fully adjusted model (i.e., model 3)
may have been overadjusted. For ex-
ample, model 3 considers prior cardio-
vascular disease as a potential confounder,
but it should be realized that cardiovascular
disease may lie on the pathway between
hyperglycemiaandlowerHRV(i.e.,maybea
mediator instead of a confounder). None-
theless, regression coefficients remained
similar to thoseofmodel 2. Fourth, 399par-
ticipants were excluded from the analyses
due to missing confounders, but we sug-
gest that the risk of selection bias was
minimal, because variable values were
similar between the included and ex-
cluded individuals. Fifth, our study pop-
ulation consisted of middle-aged Caucasians
with access to high-quality diabetes care,
so results may not be generalizable to
other populations.
In conclusion,weshowed, in apopulation-
based study, that both prediabetes, type
2 diabetes, and measures of hyperglyce-
mia are associated with cardiac auto-
nomic dysfunction, as measured by low
HRV, independently of major cardiovas-
cular risk factors. These findings support
the concept that cardiac autonomic
dysfunction precedes the clinical diag-
nosis of type 2 diabetes and may play a
role in the development of various car-
diovascular diseases, such asmyocardial
infarction and sudden cardiac death.
The current study gives further support
to the notion that prediabetes may be
considered as a potential therapeutic
target.
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